GlassScriptPhysician profile
Michael F Perry
NPI 1588761449
$4,321.93
in general payments reported to CMS, 2019-2025
24 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $640 · 2021: $863 · 2022: $883 · 2023: $727 · 2024: $374 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $671.41 | 2019-2021 | |
| Abbvie INC. | $508.25 | 2019-2023 | |
| Evofem Biosciences, INC. | $465.16 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $423.76 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $359.13 | 2021-2025 | |
| Exeltis, USA INC. | $323.89 | 2022-2025 | Slynd, Solosec |
| Therapeuticsmd, INC. | $215.59 | 2019-2022 | |
| Scynexis, INC. | $208.28 | 2021-2022 | |
| Coopersurgical, INC. | $181.20 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $164.32 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $146.31 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $123.80 | 2023-2025 | Veozah |
| Mylan Pharmaceuticals INC. | $116.08 | 2019-2022 | |
| Shield Therapeutics INC | $84.80 | 2023-2024 | Accrufer |
| Myovant Sciences INC. | $81.72 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $50.00 | 2020-2023 | Aptima |
| Myriad Women'S Health, INC. | $44.65 | 2023 | Myrisk |
| Allergan, INC. | $41.08 | 2019-2020 | |
| Medline Industries LP | $31.57 | 2019 | |
| Aspira Women'S Health INC | $20.93 | 2020 | |
| Merck Sharp & Dohme LLC | $17.17 | 2021 | |
| Organon LLC | $16.61 | 2023 | Nexplanon |
| Dysis Medical, INC. | $15.06 | 2019 | |
| Caldera Medical, INC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.